Skip to Content

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

The CAPTIVATE study is a phase II international study that evaluates the efficacy of a combination treatment of ibrutinib and venetoclax in a fixed duration as a first-line treatment for chronic lymphocytic leukemia (CLL). At ASH 2023, Professor Paolo Ghia presented the follow-up at five years of the study, on which he will elaborate in this MEDtalk.

Paolo Ghia

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top